Strategies towards personalised treatment in Juvenile Idiopathic Arthritis (JIA): An open randomised multicentre blinded-assessor trial assessing the effectiveness of intraarticular glucocorticoid injections in JIA patients starting tumour necrosis factor inhibitor treatment. The MyJIA trial.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-510118-21-00

Enrollment

188

Registered

2024-05-15

Start date

2020-12-01

Completion date

2025-02-06

Last updated

2024-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Juvenile Idiopathic Arthritis

Brief summary

The proportion of participants with sustained, inactive disease (according to the Wallace 2011 criteria) and no i.a. or p.o. glucocorticoid use from week 24 to 36.

Detailed description

30% improvement in the paediatric American College of Rheumatology criteria (ACR Pedi 30 improvement) at week 24.

Interventions

DRUGLederspan

DRUGinjektionsvæske

DRUGsuspension

Eligibility

Sex/Gender

All

Age

0 Years to 17 Years

Design outcomes

Primary

Measure	Time frame
The proportion of participants with sustained, inactive disease (according to the Wallace 2011 criteria) and no i.a. or p.o. glucocorticoid use from week 24 to 36.	—

Secondary

Measure	Time frame
30% improvement in the paediatric American College of Rheumatology criteria (ACR Pedi 30 improvement) at week 24.	—

Countries

Norway

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026